Quantum chemical optimization and residue-specific stabilization of CDK20 inhibitors in hepatocellular carcinoma (original) (raw)

• Rawla P, Sunkara T, Muralidharan P, Raj JP (2018) Update in global trends and aetiology of hepatocellular carcinoma. Contemp Oncol 22:141–150. https://doi.org/10.5114/wo.2018.78941
• Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74(3):229–263. https://doi.org/10.3322/caac.21763
  Article PubMed Google Scholar
• Kim DY (2024) Changing etiology and epidemiology of hepatocellular carcinoma: Asia and worldwide. J Liver Cancer 24:62–70. https://doi.org/10.17998/jlc.2024.03.13
• European Association for the Study of the Liver (2012) EASL clinical practical guidelines: management of alcoholic liver disease. J Hepatol 57(2):399–420. https://doi.org/10.1016/j.jhep.2012.04.004
  Article Google Scholar
• Rinella ME, Sookoian S (2024) From NAFLD to MASLD: updated naming and diagnosis criteria for fatty liver disease. J Lipid Res. https://doi.org/10.1016/j.jlr.2023.100430
  Article PubMed Google Scholar
• Song SJ, Lai JC-T, Wong GL-H, Wong VW-S, Yip TC-F (2024) Can we use old NAFLD data under the new MASLD definition? J Hepatol 80(2):e54–e56. https://doi.org/10.1016/j.jhep.2023.10.029
  Article CAS PubMed Google Scholar
• Testino G, Caputo F (2024) Alcohol-related liver disease. Hepatobiliary Surg Nutr 13(2):347. https://doi.org/10.21037/hbsn-23-191
  Article PubMed PubMed Central Google Scholar
• Dhanasekaran R, Suzuki H, Lemaitre L, Kubota N, Hoshida Y (2025) Molecular and immune landscape of hepatocellular carcinoma to guide therapeutic decision-making. Hepatology 81(3):1038–1057. https://doi.org/10.1097/hep.0000000000000000
  Article PubMed Google Scholar
• Shibata T (2021) Genomic landscape of hepatocarcinogenesis. J Hum Genet 66(9):845–851. https://doi.org/10.1038/s10038-021-00928-6
  Article CAS PubMed Google Scholar
• Toh TB, Lim JJ, Chow EK-H (2019) Epigenetics of hepatocellular carcinoma. Clin Transl Med 8(1):13. https://doi.org/10.1186/s40169-019-0233-7
  Article PubMed PubMed Central Google Scholar
• Chang YS, Tu SJ, Chen HD, Hsu MH, Chen YC, Chao DS, Chung CC, Chou YP, Chang CM, Lee YT (2023) Integrated genomic analyses of hepatocellular carcinoma. Hepatol Int 17(1):97–111. https://doi.org/10.1007/s12072-022-10400-1
  Article PubMed Google Scholar
• Ganini C, Amelio I, Bertolo R, Bove P, Buonomo OC, Candi E, Cipriani C, Di Daniele N, Juhl H, Mauriello A (2021) Global mapping of cancers: the cancer genome atlas and beyond. Mol Oncol 15(11):2823–2840. https://doi.org/10.1002/1878-0261.13010
  Article PubMed PubMed Central Google Scholar
• Becht R, Kiełbowski K, Wasilewicz MP (2024) New opportunities in the systemic treatment of hepatocellular carcinoma—today and tomorrow. Int J Mol Sci 25(3):1456. https://doi.org/10.3390/ijms25031456
  Article CAS PubMed PubMed Central Google Scholar
• Ghaziani TT, Dhanasekaran R (2021) Recent progress in systemic therapy for hepatocellular cancer (HCC). Curr Treat Options Gastroenterol 19:351–368. https://doi.org/10.1007/s11938-021-00343-7
  Article PubMed PubMed Central Google Scholar
• Lazzaro A, Hartshorn KL (2023) A comprehensive narrative review on the history, current landscape, and future directions of hepatocellular carcinoma (HCC) systemic therapy. Cancers (Basel) 15(9):2506. https://doi.org/10.3390/cancers15092506
  Article CAS PubMed Google Scholar
• Sadagopan N, He AR (2024) Recent progress in systemic therapy for advanced hepatocellular carcinoma. Int J Mol Sci 25(2):1259. https://doi.org/10.3390/ijms25021259
  Article CAS PubMed PubMed Central Google Scholar
• Selene II, Ozen M, Patel RA (2024) Hepatocellular carcinoma: advances in systemic therapy. Semin Intervent Radiol 41(1):56–62
  Article PubMed PubMed Central Google Scholar
• Zhang H, Zhang W, Jiang L, Chen Y (2022) Recent advances in systemic therapy for hepatocellular carcinoma. Biomark Res 10:1–21. https://doi.org/10.1186/s40364-022-00359-7
  Article Google Scholar
• Ben Khaled N, Zarka V, Hobeika B, Schneider J, Rau M, Weich A, Leicht HB, Ye L, Piseddu I, Dill MT (2025) Therapeutic sequences of systemic therapy after atezolizumab plus bevacizumab for hepatocellular carcinoma: real-world analysis of the IMMUreal cohort. Aliment Pharmacol Ther 59(4):587–587. https://doi.org/10.1111/apt.17851
  Article Google Scholar
• Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim T-Y, Kudo M, Breder V, Merle P, Kaseb AO (2020) Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 382(20):1894–1905. https://doi.org/10.1056/NEJMoa1915745
  Article CAS PubMed Google Scholar
• Hiraoka A, Kumada T, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S (2022) Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: early clinical experience. Cancer Rep 5(2):e1464. https://doi.org/10.1002/cnr2.1464
  Article CAS Google Scholar
• Kudo M (2020) A new era in systemic therapy for hepatocellular carcinoma: atezolizumab plus bevacizumab combination therapy. Liver Cancer 9(2):119–137. https://doi.org/10.1159/000507767
  Article CAS PubMed PubMed Central Google Scholar
• Terashima T, Kido H, Takata N, Hayashi T, Seki A, Nakagawa H, Nio K, Toyama T, Iida N, Yamada S (2025) Phase II study of atezolizumab and bevacizumab combination therapy for patients with advanced hepatocellular carcinoma previously treated with lenvatinib. Cancers 17(2):278. https://doi.org/10.3390/cancers17020278
  Article CAS PubMed PubMed Central Google Scholar
• Ventura I, Sanchiz L, Legidos-García ME, Murillo-Llorente MT, Pérez-Bermejo M (2023) Atezolizumab and bevacizumab combination therapy in the treatment of advanced hepatocellular cancer. Cancers (Basel) 16(1):197. https://doi.org/10.3390/cancers16010197
  Article CAS PubMed Google Scholar
• Vogel A, Finn RS, Blanchet Zumofen M-H, Heuser C, Sanchez Alvarez J, Leibfried M, Mitchell CR, Batson S, Redhead G, Gaillard VE (2023) Atezolizumab in combination with bevacizumab for the management of patients with hepatocellular carcinoma in the first-line setting: systematic literature review and meta-analysis. Liver Cancer 12(6):510–520. https://doi.org/10.1159/000531626
  Article CAS PubMed PubMed Central Google Scholar
• Yang X, Wang D, Lin J, Yang X, Zhao H (2020) Atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma. Lancet Oncol 21(9):e412. https://doi.org/10.1016/S1470-2045(20)30480-7
  Article PubMed Google Scholar
• Chivukula S, Malkhed V (2023) The role of CDK20 protein in carcinogenesis. Curr Drug Targets 24(10):790–796. https://doi.org/10.2174/1389450123666230605091720
  Article CAS PubMed Google Scholar
• Greten TF, Korangy F (2018) CDK20 inhibition and immune checkpoint blockade: bringing cancer biology and tumour immunology together to develop novel treatment options for HCC. Gut 67(5):783–784. https://doi.org/10.1136/gutjnl-2017-314549
  Article CAS PubMed Google Scholar
• Zheng J, Wang S, Xia L, Sun Z, Chan KM, Bernards R, Qin W, Chen J, Xia Q, Jin H (2025) Hepatocellular carcinoma: signaling pathways and therapeutic advances. Signal Transduct Target Ther 10(1):35. https://doi.org/10.1038/s41392-024-01670-0
  Article PubMed PubMed Central Google Scholar
• Ren F, Ding X, Zheng M, Korzinkin M, Cai X, Zhu W, Mantsyzov A, Aliper A, Aladinskiy V, Cao Z (2023) Alphafold accelerates artificial intelligence powered drug discovery: efficient discovery of a novel CDK20 small molecule inhibitor. Chem Sci 14(6):1443–1452. https://doi.org/10.1039/D3SC00561D
  Article CAS PubMed PubMed Central Google Scholar
• Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, Tunyasuvunakool K, Bates R, Žídek A, Potapenko A (2021) Highly accurate protein structure prediction with AlphaFold. Nature 596(7873):583–589. https://doi.org/10.1038/s41586-021-03819-2
  Article CAS PubMed PubMed Central Google Scholar
• Varadi M, Anyango S, Deshpande M, Nair S, Natassia C, Yordanova G, Yuan D, Stroe O, Wood G, Laydon A (2022) AlphaFold protein structure database: massively expanding the structural coverage of protein-sequence space with high-accuracy models. Nucleic Acids Res 50(D1):D439–D444. https://doi.org/10.1093/nar/gkab1061
  Article CAS PubMed Google Scholar
• Varadi M, Bertoni D, Magana P, Paramval U, Pidruchna I, Radhakrishnan M, Tsenkov M, Nair S, Mirdita M, Yeo J (2024) Alphafold protein structure database in 2024: providing structure coverage for over 214 million protein sequences. Nucleic Acids Res 52(D1):D368–D375. https://doi.org/10.1093/nar/gkad888
  Article CAS PubMed Google Scholar
• Kim S, Bolton EE (2024) PubChem: a large‐scale public chemical database for drug discovery. In: Open Access Databases and Datasets for Drug Discovery, pp 39–66
• Kim S, Chen J, Cheng T, Gindulyte A, He J, He S, Li Q, Shoemaker BA, Thiessen PA, Yu B (2025) PubChem 2025 update. Nucleic Acids Res 53(D1):D1516–D1525. https://doi.org/10.1093/nar/gkab1075
  Article CAS PubMed Google Scholar
• Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE (2004) UCSF chimera—a visualization system for exploratory research and analysis. J Comput Chem 25(13):1605–1612. https://doi.org/10.1002/jcc.20084
  Article CAS PubMed Google Scholar
• Labbé CM, Rey J, Lagorce D, Vavruša M, Becot J, Sperandio O, Villoutreix BO, Tufféry P, Miteva MA (2015) MTiopenscreen: a web server for structure-based virtual screening. Nucleic Acids Res 43(W1):W448–W454. https://doi.org/10.1093/nar/gkv391
  Article CAS PubMed PubMed Central Google Scholar
• Trott O, Olson AJ (2010) Autodock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 31(2):455–461. https://doi.org/10.1002/jcc.21334
  Article CAS PubMed PubMed Central Google Scholar
• Xiong G, Wu Z, Yi J, Fu L, Yang Z, Hsieh C, Yin M, Zeng X, Wu C, Lu A et al (2021) ADMETlab 2.0: an integrated online platform for accurate and comprehensive predictions of ADMET properties. Nucleic Acids Res 49:W5–W14. https://doi.org/10.1093/nar/gkab255
• Hanasaki K, Ali ZA, Choi M, Del Ben M, Wong BM (2023) Implementation of real-time TDDFT for periodic systems in the open-source PySCF software package. J Comput Chem 44(9):980–987. https://doi.org/10.1002/jcc.26859
  Article CAS PubMed Google Scholar
• Sun Q, Berkelbach TC, Blunt NS, Booth GH, Guo S, Li Z, Liu J, McClain JD, Sayfutyarova ER, Sharma S (2018) Pyscf: the python-based simulations of chemistry framework. Wiley Interdiscip Rev Comput Mol Sci 8(1):e1340. https://doi.org/10.1002/wcms.1340
  Article CAS Google Scholar
• Landrum G (2013) RDKit: a software suite for cheminformatics, computational chemistry, and predictive modeling. Greg Landrum 8(31.10):5281
  Google Scholar
• Case DA, Aktulga HM, Belfon K, Cerutti DS, Cisneros GA, Cruzeiro VW, Forouzesh N, Giese TJ, Götz AW, Gohlke H (2023) AmberTools. J Chem Inf Model 63(20):6183–6191. https://doi.org/10.1021/acs.jcim.3c00729
  Article CAS PubMed PubMed Central Google Scholar
• Janek J, Kolafa J (2024) Novel barostat implementation for molecular dynamics. J Chem Phys. https://doi.org/10.1063/5.0000000
  Article PubMed Google Scholar
• Lin Y, Pan D, Li J, Zhang L, Shao X (2017) Application of Berendsen barostat in dissipative particle dynamics for nonequilibrium dynamic simulation. J Chem Phys 146(12):124108. https://doi.org/10.1063/1.4978807
  Article CAS PubMed Google Scholar
• Darden T, York D, Pedersen L (1993) Particle mesh Ewald: an N⋅log (N) method for Ewald sums in large systems. J Chem Phys 98(12):10089–10092. https://doi.org/10.1063/1.464397
  Article CAS Google Scholar
• Roe DR, Cheatham TE III (2013) Ptraj and cpptraj: software for processing and analysis of molecular dynamics trajectory data. J Chem Theory Comput 9(7):3084–3095. https://doi.org/10.1021/ct400341p
  Article CAS PubMed Google Scholar
• Miller BR III, McGee TD Jr, Swails JM, Homeyer N, Gohlke H, Roitberg AE (2012) MMPBSA.py: an efficient program for end-state free energy calculations. J Chem Theory Comput 8(9):3314–3321. https://doi.org/10.1021/ct300418h
  Article CAS PubMed Google Scholar
• Grant BJ, Rodrigues APC, ElSawy KM, McCammon JA, Caves LSD (2006) Bio3d: an R package for the comparative analysis of protein structures. Bioinformatics 22(21):2695–2696. https://doi.org/10.1093/bioinformatics/btl461
  Article CAS PubMed Google Scholar
• Grant BJ, Skjærven L, Yao X (2021) The bio3d packages for structural bioinformatics. Protein Sci 30(1):20–30. https://doi.org/10.1002/pro.4076
  Article CAS PubMed Google Scholar
• DeLano WL (2002) PyMOL: an open-source molecular graphics tool CCP4. Newsl Protein Crystallogr 40(1):82–92
  Google Scholar
• Kagami LP, das Neves GM, Timmers LFS, Caceres RA, Eifler-Lima VL (2020) Geo-measures: a PyMOL plugin for protein structure ensembles analysis. Comput Biol Chem 87:107322. https://doi.org/10.1016/j.compbiolchem.2020.107322
  Article CAS PubMed Google Scholar
• Zhao B-W, Su X-R, Yang Y, Li D-X, Li G-D, Hu P-W, Luo X, Hu LA (2024) Heterogeneous information network learning model with neighborhood-level structural representation for predicting lncRNA-miRNA interactions. Comput Struct Biotechnol J 23:2924–2933. https://doi.org/10.1016/j.csbj.2024.06.032
• Zhao B-W, Su X-R, Yang Y, Li D-X, Li G-D, Hu P-W, You Z-H, Luo X, Hu L (2025) Regulation-aware graph learning for drug repositioning over heterogeneous biological network. Inf Sci 686:121360. https://doi.org/10.1016/j.ins.2024.121360